Rumors suggest President Trump may reschedule marijuana from Schedule I to III. Industry leaders react with optimism and caution as the change could impact research, taxes, banking, and state policies, while critics warn of confusion and uneven effects for small businesses.
Governor Kathy Hochul demands resignations of two top New York cannabis regulators following mishandled investigations and regulatory missteps. With adult-use sales booming, the state aims to restore accountability and strengthen leadership at the Office of Cannabis Management.
Grow City CZ founder Michal Otipka has spent nearly 30 years building Europe’s most influential grow shop. From police raids to legalization, discover how his Prague-based “permanent exhibition” is reshaping home cultivation across the continent.
Congress’s 2025 spending bill includes a sweeping change to federal hemp law, redefining legal hemp and effectively banning most hemp-derived THC products. Industry leaders warn the move could “wipe out” 95% of the market, while advocates say it underscores the need for unified cannabis regulation.
Tobacco giants are investing heavily in cannabis, from R&D partnerships to vapor technology and wellness products. As integration accelerates, the focus shifts from resistance to direction—how to merge corporate infrastructure with the plant’s creative and cultural foundations.
At Expopharm and InterTabac, global strategist Deepak Anand shares insights on Canada’s hard lessons, Germany’s growing pains, India’s potential as the world’s largest cannabis market, and why access—not hype—will define the industry’s future.
Germany’s Cannabis Act evaluation shows fewer youth consumers, no rise in accidents, and declining crime. Bloomwell CEO Niklas Kouparanis warns against restricting medical access, arguing it would re-criminalize patients and undermine public health progress.
HoneyGrove Dispensary in Clementon marks its 2nd anniversary with Rich Medina, DJ Ceasar, live bands, and a car showcase. In two years, HoneyGrove has grown into a cultural anchor, blending music, community, and compliant cannabis retail in South Jersey and Philadelphia.
How will cannabis advertising change if the plant moves to Schedule III? From 280E relief to FDA oversight, discover what rescheduling means for marketing, media access, and how culture-driven brands can stay ahead.
President Donald Trump is expected to announce “Make Cannabis Great Again,” rescheduling cannabis to Schedule III. The move would legalize medical use across the U.S., spark global reforms, and trigger a worldwide race in cannabis research and development.
For the first time in Wisconsin—and following South Carolina and Minnesota—bars are pouring THC beverages on draft. From taverns to taprooms, this milestone signals a cultural shift where hemp-derived drinks join beer and cocktails in redefining America’s social rituals.
Feldman Legal Advisors has promoted Jessica Steinberg, Ph.D., to Associate in London after her admission to practice law in England and Wales, expanding the firm’s cannabis, psychedelics, and corporate practice across U.S. and European markets.
With Trump open to cannabis rescheduling and the DEA making it a priority, industry leaders see a historic shift ahead. Schedule III could ease taxes, boost research, and spur growth—but experts warn it’s only the first step toward real federal reform.
A new book by Darren Gleeman, The Cannabis ESOP Architect, reveals the only IRS-approved way for cannabis founders to sell their business tax-free, preserve culture, and permanently eliminate the burden of IRC 280E through Employee Stock Ownership Plans.
The Flowery has been named No. 86 on the 2025 Inc. 5000 list of America’s Fastest-Growing Private Companies. With 3,800% revenue growth over three years, the multi-state brand continues to expand while staying true to its culture-first mission.
